儿科抗真菌药物。
Pediatric antifungal agents.
机构信息
Department of Pediatrics, Duke University, Duke Clinical Research Institute, Durham, NC 27715, USA.
出版信息
Curr Opin Infect Dis. 2009 Dec;22(6):553-8. doi: 10.1097/QCO.0b013e3283321ccc.
PURPOSE OF REVIEW
In immunocompromised hosts, invasive fungal infections are common and fatal. In the past decade, the antifungal armamentarium against invasive mycoses has expanded greatly. The purpose of the present report is to review the most recent literature addressing the use of antifungal agents in children.
RECENT FINDINGS
Most studies evaluating the safety and efficacy of antifungal agents are limited to adults. However, important progress has been made in describing the pharmacokinetics and safety of newer antifungal agents in children, including the echinocandins.
SUMMARY
Dosage guidelines for newer antifungal agents are currently based on adult and limited pediatric data. Because important developmental pharmacology changes occur throughout childhood impacting the pharmacokinetics of these agents, antifungal studies specifically designed for children are necessary.
目的综述
在免疫功能低下的宿主中，侵袭性真菌感染很常见且致命。在过去的十年中，抗真菌药物治疗侵袭性真菌感染的手段有了很大的发展。本报告的目的是回顾最近关于儿童使用抗真菌药物的文献。
最近的发现
评估抗真菌药物安全性和疗效的大多数研究都仅限于成年人。然而，在描述新型抗真菌药物在儿童中的药代动力学和安全性方面已经取得了重要进展，包括棘白菌素类。
总结
新型抗真菌药物的剂量指南目前基于成人和有限的儿科数据。由于在儿童期整个过程中都会发生重要的发育药理学变化，这些药物的药代动力学受到影响，因此有必要专门针对儿童进行抗真菌研究。
Zotero 插件